Determination of Indapamide concentration in plasma or whole blood? [Bioanalytics]

posted by gialuu – Vietnam, 2018-09-06 06:12 (2145 d 07:11 ago) – Posting: # 19240
Views: 3,217

(edited by Ohlbe on 2018-09-06 10:26)

Thank you for your information.

Some analytical method developed in plasma matrix were published. And according to those references, they were also applied for BE studies. This makes me confused.

In the case that we have developed an analytical method for determination of Indapamide concentration in plasma and validated the method following FDA Guidelines for some criteria (specificity, sensitivity, accuracy- precision, linearity range, dilution integrity, carry over, matrix effect, stability…) like the others in which the analytes do not bind highly to red blood cells, is there any other addition criterion which has to be validated?

And please share with us some recommendations or some remarkable things while developing an analytical method in whole blood.

Thanks all!

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

UA Flag
 Admin contact
23,112 posts in 4,858 threads, 1,644 registered users;
67 visitors (0 registered, 67 guests [including 17 identified bots]).
Forum time: 13:23 CEST (Europe/Vienna)

It’s always fun to have your models validated,
but is way more fun to have them trashed.
Finding out you are completely wrong
is a great part of science.    G. Randall Gladstone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz